+44 20 8123 2220
info@marketpublishers.com

NOVARTIS, NVA237 ready to enter LAMA market: Spiriva domination under threat!!

https://marketpublishers.com/r/N3F5FF99C77EN.html
Date: June 2011
Pages: 2
Price: US$ 90.00 (Single User License)
ID: N3F5FF99C77EN

Abstracts

NVS today announced the top-line results from its second pivotal PhIII trial (GLOW2) on NVA237 (once daily LAMA), meeting both, primary and the secondary endpoints. NVA237 demonstrated comparable safety and efficacy data vs. PFE's Spiriva (once daily LAMA). Faster onset of action (5 min vs 20-30 min in tiotropium), higher selectivity for the muscarinic type-3 (M3) receptor which might potentially translated in to reduced antimuscarinic side effects is potentially how, NVS might pitch NVA237 against Spiriva. We expect NVA237 to garner upto 25% of the LAMA market growing approximately at 25%...

+44 20 8123 2220
info@marketpublishers.com

Contents

COMPANIES MENTIONED

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: NOVARTIS, NVA237 ready to enter LAMA market: Spiriva domination under threat!!
Product link: https://marketpublishers.com/r/N3F5FF99C77EN.html
Price: US$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/N3F5FF99C77EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970